High Purity New England, a supplier of equipment, process systems, and custom solutions for the biopharma industry, has appointed a new chief scientific officer, Dr. Michael Quesenberry.
 
As a biopharma industry veteran, Quesenberry will bring his wealth of bioprocessing knowledge in both cGMP manufacturing and process development to the HPNE team, helping to advance the mission of the organization as it continues its high-growth trajectory.
 
With a Ph.D in Biochemistry and Molecular Biology from Columbia University, as well as a Bachelor of Science magna cum laude in Chemistry and Biophysics from Hampden-Sydney College, Quesenberry will serve as a subject-matter expert for bioprocess development. He will also spearhead a lot of new initiatives, including new product development, employee training, and the creation of a new laboratory and specialty materials and manufacturing workshop.
 
Prior to joining the HPNE team, Quesenberry began as an instrumentation scientist supporting dynamic light scattering and circular dichroism. He then transitioned into process development work at preclinical companies like Avaxia, Xencor, and Werewolf Therapeutics, and larger Phase I/II biotechs such as BMS, Pfizer, Lonza, and Pall Life Sciences. At Pall, Quesenberry started as subject matter expert across the portfolio and finished as certified trainer for all product lines. Among his other accomplishments, he has two patents to his name, and he has published more than 16 peer-reviewed Glycobiology-focused articles in the course of his research career.